123 related articles for article (PubMed ID: 38606933)
1. An orthotopic prostate cancer model for new treatment development using syngeneic or patient-derived tumors.
Chaudary N; Wiljer E; Foltz W; Thapa P; Hill RP; Milosevic M
Prostate; 2024 Jun; 84(9):823-831. PubMed ID: 38606933
[TBL] [Abstract][Full Text] [Related]
2. A TRAMP-derived orthotopic prostate syngeneic (TOPS) cancer model for investigating anti-tumor treatments.
Lardizabal J; Ding J; Delwar Z; Rennie PS; Jia W
Prostate; 2018 May; 78(6):457-468. PubMed ID: 29450905
[TBL] [Abstract][Full Text] [Related]
3. Novel syngeneic pseudo-orthotopic prostate cancer model: vascular, mitotic and apoptotic responses to castration.
Frost GI; Lustgarten J; Dudouet B; Nyberg L; Hartley-Asp B; Borgström P
Microvasc Res; 2005 Jan; 69(1-2):1-9. PubMed ID: 15797254
[TBL] [Abstract][Full Text] [Related]
4. Germline genetic variation modulates tumor progression and metastasis in a mouse model of neuroendocrine prostate carcinoma.
Patel SJ; Molinolo AA; Gutkind S; Crawford NP
PLoS One; 2013; 8(4):e61848. PubMed ID: 23620793
[TBL] [Abstract][Full Text] [Related]
5. Mast cell targeting hampers prostate adenocarcinoma development but promotes the occurrence of highly malignant neuroendocrine cancers.
Pittoni P; Tripodo C; Piconese S; Mauri G; Parenza M; Rigoni A; Sangaletti S; Colombo MP
Cancer Res; 2011 Sep; 71(18):5987-97. PubMed ID: 21896641
[TBL] [Abstract][Full Text] [Related]
6. Icaritin suppresses development of neuroendocrine differentiation of prostate cancer through inhibition of IL-6/STAT3 and Aurora kinase A pathways in TRAMP mice.
Sun F; Zhang ZW; Tan EM; Lim ZLR; Li Y; Wang XC; Chua SE; Li J; Cheung E; Yong EL
Carcinogenesis; 2016 Jul; 37(7):701-711. PubMed ID: 27207661
[TBL] [Abstract][Full Text] [Related]
7. Repurposing of the Antiepileptic Drug Levetiracetam to Restrain Neuroendocrine Prostate Cancer and Inhibit Mast Cell Support to Adenocarcinoma.
Sulsenti R; Frossi B; Bongiovanni L; Cancila V; Ostano P; Fischetti I; Enriquez C; Guana F; Chiorino G; Tripodo C; Pucillo CE; Colombo MP; Jachetti E
Front Immunol; 2021; 12():622001. PubMed ID: 33737929
[TBL] [Abstract][Full Text] [Related]
8. The TRAMP mouse as a model for prostate cancer.
Hurwitz AA; Foster BA; Allison JP; Greenberg NM; Kwon ED
Curr Protoc Immunol; 2001 Nov; Chapter 20():20.5.1-20.5.23. PubMed ID: 18432778
[TBL] [Abstract][Full Text] [Related]
9. Ultrasound and magnetic resonance imaging for group stratification and treatment monitoring in the transgenic adenocarcinoma of the mouse prostate model.
Fagerland ST; Hill DK; van Wamel A; de Lange Davies C; Kim J
Prostate; 2020 Feb; 80(2):186-197. PubMed ID: 31763715
[TBL] [Abstract][Full Text] [Related]
10. A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential.
Masumori N; Thomas TZ; Chaurand P; Case T; Paul M; Kasper S; Caprioli RM; Tsukamoto T; Shappell SB; Matusik RJ
Cancer Res; 2001 Mar; 61(5):2239-49. PubMed ID: 11280793
[TBL] [Abstract][Full Text] [Related]
11. Raf kinase inhibitor protein (RKIP) deficiency decreases latency of tumorigenesis and increases metastasis in a murine genetic model of prostate cancer.
Escara-Wilke J; Keller JM; Ignatoski KM; Dai J; Shelley G; Mizokami A; Zhang J; Yeung ML; Yeung KC; Keller ET
Prostate; 2015 Feb; 75(3):292-302. PubMed ID: 25327941
[TBL] [Abstract][Full Text] [Related]
12. Establishment and characterization of a novel treatment-related neuroendocrine prostate cancer cell line KUCaP13.
Okasho K; Mizuno K; Fukui T; Lin YY; Kamiyama Y; Sunada T; Li X; Kimura H; Sumiyoshi T; Goto T; Kobayashi T; Lin D; Wang Y; Collins CC; Inoue T; Ogawa O; Akamatsu S
Cancer Sci; 2021 Jul; 112(7):2781-2791. PubMed ID: 33960594
[TBL] [Abstract][Full Text] [Related]
13. A novel mouse model of human prostate cancer to study intraprostatic tumor growth and the development of lymph node metastases.
Linxweiler J; Körbel C; Müller A; Hammer M; Veith C; Bohle RM; Stöckle M; Junker K; Menger MD; Saar M
Prostate; 2018 Jun; 78(9):664-675. PubMed ID: 29572953
[TBL] [Abstract][Full Text] [Related]
14. Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model.
Foster BA; Gingrich JR; Kwon ED; Madias C; Greenberg NM
Cancer Res; 1997 Aug; 57(16):3325-30. PubMed ID: 9269988
[TBL] [Abstract][Full Text] [Related]
15. Orthotopic treatment model of prostate cancer and metastasis in the immunocompetent mouse: efficacy of flt3 ligand immunotherapy.
Somers KD; Brown RR; Holterman DA; Yousefieh N; Glass WF; Wright GL; Schellhammer PF; Qian J; Ciavarra RP
Int J Cancer; 2003 Dec; 107(5):773-80. PubMed ID: 14566827
[TBL] [Abstract][Full Text] [Related]
16. Systemic Ablation of
Pulliam TL; Awad D; Han JJ; Murray MM; Ackroyd JJ; Goli P; Oakhill JS; Scott JW; Ittmann MM; Frigo DE
Cells; 2022 Jun; 11(12):. PubMed ID: 35741020
[TBL] [Abstract][Full Text] [Related]
17. Prostate tumor microenvironment alters immune cells and prevents long-term survival in an orthotopic mouse model following flt3-ligand/CD40-ligand immunotherapy.
Ciavarra RP; Holterman DA; Brown RR; Mangiotti P; Yousefieh N; Wright GL; Schellhammer PF; Glass WF; Somers KD
J Immunother; 2004; 27(1):13-26. PubMed ID: 14676630
[TBL] [Abstract][Full Text] [Related]
18. Clinical features of neuroendocrine prostate cancer.
Conteduca V; Oromendia C; Eng KW; Bareja R; Sigouros M; Molina A; Faltas BM; Sboner A; Mosquera JM; Elemento O; Nanus DM; Tagawa ST; Ballman KV; Beltran H
Eur J Cancer; 2019 Nov; 121():7-18. PubMed ID: 31525487
[TBL] [Abstract][Full Text] [Related]
19. Protective immunosurveillance and therapeutic antitumor activity of gammadelta T cells demonstrated in a mouse model of prostate cancer.
Liu Z; Eltoum IE; Guo B; Beck BH; Cloud GA; Lopez RD
J Immunol; 2008 May; 180(9):6044-53. PubMed ID: 18424725
[TBL] [Abstract][Full Text] [Related]
20. Diffusion-weighted MRI for early detection and characterization of prostate cancer in the transgenic adenocarcinoma of the mouse prostate model.
Hill DK; Kim E; Teruel JR; Jamin Y; Widerøe M; Søgaard CD; Størkersen Ø; Rodrigues DN; Heindl A; Yuan Y; Bathen TF; Moestue SA
J Magn Reson Imaging; 2016 May; 43(5):1207-17. PubMed ID: 26559017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
